Cell Therapeutics Can Sue Consultant For Advice On Off-Label Reimbursement
Executive Summary
Two years ago, Cell Therapeutics Inc. doled out $10.6 million to the federal government to resolve allegations it marketed its former leukemia drug Trisenox (arsenic trioxide) for unapproved uses. The company now has a chance to recoup its losses
You may also be interested in...
Pharma Compliance Is Big Business; Software Vendors Offer Trove Of Tools
These days, the e-mail boxes of pharmaceutical compliance officers are overflowing with offers for help. Consultants and software developers are pitching a variety of wares, from tools that block sales reps from promoting drugs off-label to software that collects aggregate spend on health care providers
Pharma Compliance Is Big Business; Software Vendors Offer Trove Of Tools
These days, the e-mail boxes of pharmaceutical compliance officers are overflowing with offers for help. Consultants and software developers are pitching a variety of wares, from tools that block sales reps from promoting drugs off-label to software that collects aggregate spend on health care providers
Health Care Fraud Investigations Bedevil Pharma Industry: If You're Not Under Investigation, It's Only Because You've Recently Settled
Two months ago, the Department of Justice held a splashy news conference to announce its record-breaking $2.3 billion settlement with Pfizer. The event, which included HHS Secretary Kathleen Sebelius, cast a spotlight on Pfizer's alleged off-label marketing and kickbacks to health care providers (1"The Pink Sheet," Sept. 7, 2009)